Physician profile
Simone E Mordas
NPI 1073507984
$7,061.82
in general payments reported to CMS, 2019-2025
34 companies · $701 in 2025
The $701 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $755 · 2021: $1,555 · 2022: $1,778 · 2023: $1,013 · 2024: $909 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,624.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $850.12 | 2019-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $801.27 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $713.61 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Exeltis, USA INC. | $511.44 | 2019-2022 | |
| Abbvie INC. | $509.80 | 2021-2023 | |
| Corium, LLC | $321.91 | 2022-2025 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $297.41 | 2022-2025 | Xifaxan |
| Bausch Health US, LLC | $289.02 | 2021-2022 | |
| Novo Nordisk INC | $268.20 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Biohaven Pharmaceuticals, INC. | $249.10 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $247.40 | 2019-2023 | Austedo |
| Esperion Therapeutics, INC. | $236.34 | 2021-2025 | Nexletol |
| Supernus Pharmaceuticals, INC. | $208.12 | 2022 | |
| Pfizer INC. | $196.99 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $172.74 | 2020-2025 | Breztri, Farxiga |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $163.74 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $142.13 | 2022 | |
| Astellas Pharma US INC | $135.55 | 2022-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $116.22 | 2021-2022 | |
| Exact Sciences Corporation | $111.64 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Dermira, INC. | $90.71 | 2020 | |
| Myriad Women'S Health, INC. | $74.46 | 2023 | Myrisk |
| Ardelyx, INC. | $59.45 | 2024-2025 | Ibsrela |
| Axsome Therapeutics, INC. | $56.18 | 2024 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $45.95 | 2022 | |
| Abbott Laboratories | $27.70 | 2025 | Proclaim |
| Corcept Therapeutics | $24.63 | 2025 | Korlym |
| Endo Pharmaceuticals INC. | $24.17 | 2021 | |
| Glaxosmithkline, LLC. | $22.84 | 2025 | Arexvy, Shingrix |
| Lucid Diagnostics INC. | $22.76 | 2024 | |
| Shire North American Group INC | $20.28 | 2019 | |
| Merck Sharp & Dohme LLC | $19.42 | 2019 | |
| Phadia US INC. | $18.03 | 2021 | |
| Ironshore Pharmaceuticals INC. | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simone Mordas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.